Abstract
Previous studies have shown that calcium channel blockers may reduce the development of experimental atherosclerosis, and that nifedipine may slow the progression of coronary atherosclerosis in humans. The mechanisms responsible for this antiatherogenic effect are still unclear. It has been recently proposed that oxygen free radicals can induce the oxidation of human low-density lipoproteins (LDL) and that oxidized LDL may be an atherogenic stimulus. Previous studies in other systems have shown that calcium channel blockers may effectively inhibit oxygen radical-induced lipid peroxidation in vitro. Thus, the aim of the present study was to investigate whether calcium channel blockers may also reduce LDL modifications induced by oxygen radicals. Isolated human LDL were exposed to oxygen radicals generated by CuSO4 (10 μM for 18 hours) after a 30 minute preincubation with different concentrations (1-100 μM) of nifedipine, diltiazem, and verapamil. Lipid peroxidation was measured from malonyldihaldehyde (MDA) production. Oxygen radical-induced damage on apolipoprotein-B100 was evaluated by acrylamide and agarose gel electrophoresis. Calcium channel blockers dose-dependently prevented oxidation of both the lipid and protein components of LDL. MDA formation was reduced in LDL pre-incubated with calcium antagonists before exposure to oxygen radicals (% MDA inhibition was 89.8 ± 6.9 with 30 μM nifedipine, 68.6 ± 4.9 with 30 μM verapamil, and 68.6 ± 7.1 with 30 μM diltiazem; p <0.01 vs. controls). Similarly, apolipoprotein-B100 integrity was preserved against oxygen radical attack in the presence of calcium antagonists. Thus, calcium channel blockers reduce the oxidation of human LDL in vitro. These data suggest that reduced formation of atherogenic oxidized LDL may be an additional mechanism for the antiatherosclerotic effects of calcium channel blockers in vivo.
| Original language | English |
|---|---|
| Pages (from-to) | 417-424 |
| Number of pages | 8 |
| Journal | Cardiovascular Drugs and Therapy |
| Volume | 10 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1996 |
Fingerprint
Keywords
- Atherosclerosis
- Calcium channel-blockers
- Low density lipoprotein
- Oxygen radicals
- Peroxidation
ASJC Scopus subject areas
- Pharmacology (medical)
- Cardiology and Cardiovascular Medicine
- Pharmacology
Cite this
Calcium-channel blockers inhibit human low density lipoprotein oxidation by oxygen radicals. / Napoli, Claudio; Chiariello, Massimo; Palumbo, Giuseppe; Ambrosio, Giuseppe.
In: Cardiovascular Drugs and Therapy, Vol. 10, No. 4, 1996, p. 417-424.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Calcium-channel blockers inhibit human low density lipoprotein oxidation by oxygen radicals
AU - Napoli, Claudio
AU - Chiariello, Massimo
AU - Palumbo, Giuseppe
AU - Ambrosio, Giuseppe
PY - 1996
Y1 - 1996
N2 - Previous studies have shown that calcium channel blockers may reduce the development of experimental atherosclerosis, and that nifedipine may slow the progression of coronary atherosclerosis in humans. The mechanisms responsible for this antiatherogenic effect are still unclear. It has been recently proposed that oxygen free radicals can induce the oxidation of human low-density lipoproteins (LDL) and that oxidized LDL may be an atherogenic stimulus. Previous studies in other systems have shown that calcium channel blockers may effectively inhibit oxygen radical-induced lipid peroxidation in vitro. Thus, the aim of the present study was to investigate whether calcium channel blockers may also reduce LDL modifications induced by oxygen radicals. Isolated human LDL were exposed to oxygen radicals generated by CuSO4 (10 μM for 18 hours) after a 30 minute preincubation with different concentrations (1-100 μM) of nifedipine, diltiazem, and verapamil. Lipid peroxidation was measured from malonyldihaldehyde (MDA) production. Oxygen radical-induced damage on apolipoprotein-B100 was evaluated by acrylamide and agarose gel electrophoresis. Calcium channel blockers dose-dependently prevented oxidation of both the lipid and protein components of LDL. MDA formation was reduced in LDL pre-incubated with calcium antagonists before exposure to oxygen radicals (% MDA inhibition was 89.8 ± 6.9 with 30 μM nifedipine, 68.6 ± 4.9 with 30 μM verapamil, and 68.6 ± 7.1 with 30 μM diltiazem; p <0.01 vs. controls). Similarly, apolipoprotein-B100 integrity was preserved against oxygen radical attack in the presence of calcium antagonists. Thus, calcium channel blockers reduce the oxidation of human LDL in vitro. These data suggest that reduced formation of atherogenic oxidized LDL may be an additional mechanism for the antiatherosclerotic effects of calcium channel blockers in vivo.
AB - Previous studies have shown that calcium channel blockers may reduce the development of experimental atherosclerosis, and that nifedipine may slow the progression of coronary atherosclerosis in humans. The mechanisms responsible for this antiatherogenic effect are still unclear. It has been recently proposed that oxygen free radicals can induce the oxidation of human low-density lipoproteins (LDL) and that oxidized LDL may be an atherogenic stimulus. Previous studies in other systems have shown that calcium channel blockers may effectively inhibit oxygen radical-induced lipid peroxidation in vitro. Thus, the aim of the present study was to investigate whether calcium channel blockers may also reduce LDL modifications induced by oxygen radicals. Isolated human LDL were exposed to oxygen radicals generated by CuSO4 (10 μM for 18 hours) after a 30 minute preincubation with different concentrations (1-100 μM) of nifedipine, diltiazem, and verapamil. Lipid peroxidation was measured from malonyldihaldehyde (MDA) production. Oxygen radical-induced damage on apolipoprotein-B100 was evaluated by acrylamide and agarose gel electrophoresis. Calcium channel blockers dose-dependently prevented oxidation of both the lipid and protein components of LDL. MDA formation was reduced in LDL pre-incubated with calcium antagonists before exposure to oxygen radicals (% MDA inhibition was 89.8 ± 6.9 with 30 μM nifedipine, 68.6 ± 4.9 with 30 μM verapamil, and 68.6 ± 7.1 with 30 μM diltiazem; p <0.01 vs. controls). Similarly, apolipoprotein-B100 integrity was preserved against oxygen radical attack in the presence of calcium antagonists. Thus, calcium channel blockers reduce the oxidation of human LDL in vitro. These data suggest that reduced formation of atherogenic oxidized LDL may be an additional mechanism for the antiatherosclerotic effects of calcium channel blockers in vivo.
KW - Atherosclerosis
KW - Calcium channel-blockers
KW - Low density lipoprotein
KW - Oxygen radicals
KW - Peroxidation
UR - http://www.scopus.com/inward/record.url?scp=0029860461&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029860461&partnerID=8YFLogxK
U2 - 10.1007/BF00051106
DO - 10.1007/BF00051106
M3 - Article
C2 - 8924055
AN - SCOPUS:0029860461
VL - 10
SP - 417
EP - 424
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
SN - 0920-3206
IS - 4
ER -